Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30541651 | 1.00 | CYP2D6 (0.39) | CYP2D6GPR119KCNJ1PTGS2USP2 | |
| SCHEMBL25367480 | 0.93 | KCNJ1 (0.38) | CYP2D6GPR119KCNJ1PTGS2USP2 | |
| SCHEMBL30541598 | 0.93 | KCNJ1 (0.38) | CYP2D6GPR119KCNJ1PTGS2USP2 | |
| SCHEMBL30541620 | 0.93 | PTGS2 (0.38) | CYP2D6GPR119PTGS2PTGS1 | |
| SCHEMBL25368481 | 0.93 | PTGS2 (0.38) | CYP2D6GPR119PTGS2PTGS1 | |
| SCHEMBL25365387 | 0.91 | GPR119 (0.39) | GPR119PTGS2PTGS1JAK2JAK3 | |
| SCHEMBL30541577 | 0.91 | GPR119 (0.39) | GPR119PTGS2PTGS1JAK2JAK3 | |
| SCHEMBL25365280 | 0.89 | PTGS2 (0.36) | GPR119PTGS2USP2CYP2C19PTGS1 | |
| SCHEMBL30541568 | 0.89 | PTGS2 (0.36) | GPR119PTGS2USP2CYP2C19PTGS1 | |
| SCHEMBL25365511 | 0.88 | JAK2 (0.37) | KCNJ1PTGS2PTGS1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | claimed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | claimed |
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163054-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | CYP2D6 4333/4885GPR119 79/4885KCNJ1 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.